Univariate analysis of cumulative incidence of clinically significant (II-IV and III-IV) acute GVHD in correlation with heparanase SNP discrepancy between recipients and donors
| Grade . | Recipient-donor pair . | Cumulative incidence, % . | 95% CI for cumulative incidence . | χ2/P . |
|---|---|---|---|---|
| II-IV | HR-HR | 40.2 | 26.4-61.3 | 33.5/< .001 |
| HR-MR | 74.1 | 59.4-92.5 | ||
| HR-LR | 63.6 | 40.7-99.5 | ||
| MR-MR | 38.2 | 29.0-50.5 | ||
| MR-LR | 52.6 | 34.4-80.6 | ||
| MR-HR | 45.2 | 28.5-71.6 | ||
| LR-LR | 23.3 | 13.9-39.0 | ||
| LR-MR | 29.7 | 17.6-49.9 | ||
| LR-HR | 17.9 | 6.4-50.2 | ||
| III-IV | HR-HR | 29.2 | 16.8-50.7 | 40.4/< .001 |
| HR-MR | 59.6 | 41.7-85.2 | ||
| HR-LR | 63.6 | 40.7-99.5 | ||
| MR-MR | 19.6 | 12.2-31.4 | ||
| MR-LR | 35.8 | 18.7-68.5 | ||
| MR-HR | 19.7 | 7.1-54.3 | ||
| LR-LR | 13.6 | 6.5-28.7 | ||
| LR-MR | 12.0 | 4.8-30.0 | ||
| LR-HR | 12.8 | 3.5-47.2 |
| Grade . | Recipient-donor pair . | Cumulative incidence, % . | 95% CI for cumulative incidence . | χ2/P . |
|---|---|---|---|---|
| II-IV | HR-HR | 40.2 | 26.4-61.3 | 33.5/< .001 |
| HR-MR | 74.1 | 59.4-92.5 | ||
| HR-LR | 63.6 | 40.7-99.5 | ||
| MR-MR | 38.2 | 29.0-50.5 | ||
| MR-LR | 52.6 | 34.4-80.6 | ||
| MR-HR | 45.2 | 28.5-71.6 | ||
| LR-LR | 23.3 | 13.9-39.0 | ||
| LR-MR | 29.7 | 17.6-49.9 | ||
| LR-HR | 17.9 | 6.4-50.2 | ||
| III-IV | HR-HR | 29.2 | 16.8-50.7 | 40.4/< .001 |
| HR-MR | 59.6 | 41.7-85.2 | ||
| HR-LR | 63.6 | 40.7-99.5 | ||
| MR-MR | 19.6 | 12.2-31.4 | ||
| MR-LR | 35.8 | 18.7-68.5 | ||
| MR-HR | 19.7 | 7.1-54.3 | ||
| LR-LR | 13.6 | 6.5-28.7 | ||
| LR-MR | 12.0 | 4.8-30.0 | ||
| LR-HR | 12.8 | 3.5-47.2 |
Significant deviations (P < .05) are marked in bold.